Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 4/20 | 0.53 |
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929814 | 0.85 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL26613449 | 0.83 | MAPK10 (0.57) | TP53CNR1CNR2MMP1MMP9 | |
| SCHEMBL20508315 | 0.81 | TRPV1 (0.59) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL13210534 | 0.80 | TP53 (0.73) | TP53HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL28507937 | 0.79 | GAA (0.57) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL11898604 | 0.78 | TP53 (0.57) | TP53GSK3AGSK3BMAPTALDH1A1 | |
| SCHEMBL20509078 | 0.78 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL882739 | 0.77 | F2R (0.59) | TP53HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL27894588 | 0.77 | MAP4K4 (0.53) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30444576 | 0.76 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | TP53 4548/4885HDAC1 72/4885HDAC2 222/4885 |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LCT, AGXT, PRXL2A | TP53 4457/4885HDAC1 107/4885HDAC2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.